Description

Why Viatris Pipeline Progress Matters More Than The 2% Growth Outlook

Viatris has presented a summary of its financial performance and strategic initiatives for 2025 while outlining its expectations for 2026. Positives of the results include a revenue growth of approximately 2% compared to the prior year, excluding the impact from their Indore facility issues. The company reported $14.3 billion in total revenues for 2025 with an adjusted EBITDA of $4.2 billion. Notably, Viatris points to a robust R&D outcome with positive Phase III trials and significant regulatory advancements for certain assets. They highlight the full enrollment progress in Phase III trials for cenerimod and selatogrel and anticipate full enrollment for these programs in 2026. The initiation of multiple late-stage development programs demonstrates an ongoing investment in their pipeline. Furthermore, Viatris highlights a strong commitment to returning capital to shareholders, having returned over $1 billion through dividends and share repurchases.